Beclometasone/formoterol (Fostair®) for asthma. HTA ID: 23038

Assessment Status Rapid Review Complete
HTA ID 23038
Drug Beclometasone/formoterol
Brand Fostair®
Indication Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA.
Assessment Process
Rapid review commissioned 10/07/2023
Rapid review completed 20/07/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Fostair® for this indication not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.